BioCryst Pharmaceuticals, Inc.
BCRX
$7.96
$0.111.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.38% | 45.85% | 41.67% | 36.00% | 29.92% |
| Total Other Revenue | -- | -91.00% | -79.78% | 5.20% | -29.81% |
| Total Revenue | 45.38% | 45.85% | 41.67% | 36.00% | 29.92% |
| Cost of Revenue | -4.08% | -7.08% | -15.84% | -13.71% | -11.88% |
| Gross Profit | 91.24% | 105.31% | 129.82% | 129.85% | 131.91% |
| SG&A Expenses | 33.40% | 33.99% | 28.48% | 24.71% | 25.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.81% | 15.01% | 6.83% | 5.36% | 5.52% |
| Operating Income | 312.70% | 197.85% | 139.09% | 97.43% | 66.67% |
| Income Before Tax | 94.67% | 78.02% | 75.46% | 61.56% | 47.08% |
| Income Tax Expenses | 801.95% | 723.58% | 57,100.00% | 521.61% | -116.95% |
| Earnings from Continuing Operations | 92.91% | 75.53% | 74.37% | 60.77% | 47.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.91% | 75.53% | 74.37% | 60.77% | 47.61% |
| EBIT | 312.70% | 197.85% | 139.09% | 97.43% | 66.67% |
| EBITDA | 338.42% | 208.60% | 144.11% | 100.49% | 68.35% |
| EPS Basic | 92.87% | 76.38% | 75.80% | 63.50% | 51.58% |
| Normalized Basic EPS | 100.00% | 80.85% | 72.19% | 57.85% | 46.44% |
| EPS Diluted | 91.96% | 75.52% | 75.66% | 63.40% | 51.37% |
| Normalized Diluted EPS | 99.04% | 80.49% | 72.17% | 57.85% | 46.44% |
| Average Basic Shares Outstanding | 1.85% | 3.63% | 5.51% | 7.56% | 8.83% |
| Average Diluted Shares Outstanding | 5.07% | 5.71% | 6.33% | 7.56% | 8.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |